Literature DB >> 17079662

Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy.

YogendraSinh H Raol1, Ingrid V Lund, Sabita Bandyopadhyay, Guojun Zhang, Daniel S Roberts, John H Wolfe, Shelley J Russek, Amy R Brooks-Kayal.   

Abstract

Differential expression of GABA(A) receptor (GABR) subunits has been demonstrated in hippocampus from patients and animals with temporal lobe epilepsy (TLE), but whether these changes are important for epileptogenesis remains unknown. Previous studies in the adult rat pilocarpine model of TLE found reduced expression of GABR alpha1 subunits and increased expression of alpha4 subunits in dentate gyrus (DG) of epileptic rats compared with controls. To investigate whether this altered subunit expression is a critical determinant of spontaneous seizure development, we used adeno-associated virus type 2 containing the alpha4 subunit gene (GABRA4) promoter to drive transgene expression in DG after status epilepticus (SE). This novel use of a condition-dependent promoter upregulated after SE successfully increased expression of GABR alpha1 subunit mRNA and protein in DG at 1-2 weeks after SE. Enhanced alpha1 expression in DG resulted in a threefold increase in mean seizure-free time after SE and a 60% decrease in the number of rats developing epilepsy (recurrent spontaneous seizures) in the first 4 weeks after SE. These findings provide the first direct evidence that altering GABR subunit expression can affect the development of epilepsy and suggest that alpha1 subunit levels are important determinants of inhibitory function in hippocampus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079662      PMCID: PMC6674546          DOI: 10.1523/JNEUROSCI.3329-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  71 in total

1.  Adenosine kinase as a target for therapeutic antisense strategies in epilepsy.

Authors:  Panos Theofilas; Sukhmani Brar; Kerry-Ann Stewart; Hai-Ying Shen; Ursula S Sandau; David Poulsen; Detlev Boison
Journal:  Epilepsia       Date:  2011-01-28       Impact factor: 5.864

Review 2.  Gene therapy for epilepsy.

Authors:  David W McCandless; Jeffrey W McCandless
Journal:  Metab Brain Dis       Date:  2010-09-23       Impact factor: 3.584

3.  Amygdala-specific reduction of alpha1-GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 4.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

5.  On demand up-regulation of therapeutic genes in the brain: fiction or reality?

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2007 May-Jun       Impact factor: 7.500

6.  Effect of the alpha subunit subtype on the macroscopic kinetic properties of recombinant GABA(A) receptors.

Authors:  Amber J Picton; Janet L Fisher
Journal:  Brain Res       Date:  2007-07-10       Impact factor: 3.252

7.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 8.  Is epilepsy a preventable disorder? New evidence from animal models.

Authors:  Kathryn A Giblin; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2010-06       Impact factor: 7.519

Review 9.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

10.  A rat model of epilepsy in women: a tool to study physiological interactions between endocrine systems and seizures.

Authors:  Helen E Scharfman; Gauri H Malthankar-Phatak; Daniel Friedman; Patrice Pearce; Daniel P McCloskey; Cynthia L Harden; Neil J Maclusky
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.